BioNTech's September Test: Can the Oncology Story Stand Without Moderna's Tailwind?
Published on 08/25/2026 at 11:12 | Redaktion boerse-global.de
The rally in BioNTech shares has been remarkable — and, by the company's own admission, largely borrowed. Over the past seven trading sessions, the stock has climbed 22 percent to €97.60, with a 21 percent gain over the past month. But the catalyst didn't originate in Mainz. It came from Cambridge, Massachusetts, where Moderna's positive Phase-3 data for its mRNA cancer vaccine — developed with Merck and tested alongside Keytruda in melanoma patients — marked the first successful late-stage trial for an mRNA-based cancer therapy. Moderna's shares surged 176.97 percent in response.
BioNTech, which operates its own oncology pipeline in a closely related field, was swept up in the sector-wide enthusiasm without having delivered the study itself. The question now facing investors is whether that borrowed momentum can hold — or whether the company's own clinical data will justify the move.
A Pause After the Surge
The stock slipped 3.0 percent on Monday to €96.80, a pullback that fits into broader profit-taking across the biotech sector. Yet even after that dip, the shares remain 21 percent above their level of seven sessions ago and 20 percent higher than 30 days back. The retreat looks technical in nature — a consolidation after a sharp run rather than a fundamental reassessment.
Still, the dynamics are delicate. Stocks that rise quickly can fall disproportionately when skepticism sets in, and the valuation debate swirling around Moderna has begun to spill over into the wider mRNA complex. Simply Wall St has flagged Moderna as overvalued following its surge, noting a price-to-sales ratio of 26.0 against a modeled fair value of roughly 4.5. Skeptics also caution that the trial success has only been demonstrated in melanoma, not across other cancer types — a limitation that matters for a sector trading on broad thematic enthusiasm.
Seoul as the Defining Moment
The real test arrives in September. From the 12th through the 15th, BioNTech will present new data at the World Conference on Lung Cancer in Seoul, focusing on its lung cancer development program. At the center is a combination that hasn't been seen before: the PD-(L)1xVEGF bispecific Pumitamig paired with the B7H3-directed antibody-drug conjugate Elfetabart Drozuntecan, targeting advanced or metastatic lung cancer. These would be the first global data on this specific pairing.
Should investors sell immediately? Or is it worth buying BioNTech?
If the results convince, BioNTech positions itself as a pioneer in complex combination strategies in oncology — a field where competitors are only beginning to organize. Pumitamig has already shown encouraging efficacy at the ASCO congress in combination with chemotherapy across various PD-L1 expression levels in non-small cell lung cancer, marking the third consistent global dataset for the drug. That builds confidence, but it doesn't replace the curiosity about how the new Seoul combination will perform.
Leadership Transition and Capital Discipline
Running in parallel is a leadership change: Guido Oelkers was appointed as the future CEO about three weeks ago and will take over from Ugur Sahin no later than February 1, 2027. Since that announcement, the stock has gained 24.3 percent — though whether that reflects approval of the appointment or simply the sector rally is difficult to separate.
BioNTech is also maintaining a share buyback program of up to $1 billion, having repurchased approximately 1.7 million ADS in the second quarter. That signals confidence in the company's own valuation, independent of the market's mood swings. The balance sheet remains robust with €16.6 billion in cash, and the oncology pipeline spans fourteen registration-relevant studies — fundamentals that give the sentiment a real foundation, even if the immediate trigger came from outside.
Technical Signals and Divergent Views
Wall Street Zen recently downgraded the stock from "Hold" to "Sell" about two weeks ago — since then, the shares have risen 20.8 percent, a reminder of how sector momentum can override individual opinions in the short term. With an RSI of 71.7 and annualized volatility of 66 percent, the stock sits in technically overbought territory, trading 7.8 percent below its 52-week high of €105.80. The shares remain roughly 42 percent above their 52-week low of €68.35, suggesting the underlying uptrend remains structurally intact.
The bull case rests on continued sector-wide revaluation of mRNA oncology. Analysts point to a valuation gap of around 29.5 percent between biotech indices IDNA and XBI as potential upside. The bear case centers on contagion risk: if Moderna's price-to-sales multiple is exposed as excessive and the market corrects, skepticism could spread to related mRNA names regardless of how advanced BioNTech's own pipeline actually is.
The core question isn't whether BioNTech has benefited from Moderna's euphoria — that's undisputed. It's whether Seoul delivers what the share price is already anticipating: independent proof that the oncology story holds, with or without external tailwinds. If the market begins to differentiate more sharply between actual trial results and price fantasy, BioNTech will be judged increasingly on its own clinical substance rather than sector sentiment.
Ad
BioNTech Stock: New Analysis - 25 August
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
